After a deadly clinical trial, will immune therapies for cancer be a bust?
By Damian Garde,
STAT
| 07. 08. 2016
Immune therapies have been hailed as the future of cancer treatments, with new drugs racking up excellent clinical results by turning the body’s natural defenses on tumors.
But Thursday’s news that three patients died in a trial of one such treatment has surprised oncologists and biotech investors, casting doubts on what looked like a blockbuster new approach to fighting cancer.
Here’s a rundown on the fatal trial and what it means for the rest of the field.
Continue reading on STAT
Image via Flickr/NIH Image Gallery
Related Articles
By Katie Bo Lillis and Zachary Cohen, CNN | 09.18.2026
The intelligence report, circulated across the US military this spring in the midst of the war with Iran, immediately set off alarm bells: A Chinese ship in the Middle East was transporting components of a nuclear weapons program.
The US...
By Gay Pasley, Essence | 09.04.2026
That is what makes the unfolding case of McKenna West so important. It is more than a disagreement about abortion or a dispute over a surrogacy contract. It asks whether an agreement signed before a pregnancy can become authority...
By Anna L. Philippe, Pop Panic | 09.17.2026
What does it mean when education is considered a threat to population? As an education student, I am interested in the ways population panics are essentialized and circulated in formal education settings. Schools can play a major role in shaping...
By Ava Kofman, The New Yorker | 09.15.2026
A WOMAN WHO ACTS AS A SURROGATE, carrying a child for someone else, is said to be going on a “journey.”
Kayla Elliott started her surrogacy journey at the age of twenty-six. She gave birth to a baby girl for...
